Genentech's Lymphoma Drug Combo Wows in Mid-Stage Trial Post author:Sam Post published:December 10, 2017 Post category:BioPharma These data led to FDA Breakthrough Therapy and EMA PRIME (PRIority MEdicines) designations. Source: BioSpace You Might Also Like 2 Biotechs That Could be the Next M&A Targets September 7, 2017 <b>VenatoRx Pharma</b> Banks $42 Million to Advance Antibiotics Pipeline July 24, 2017 DNAnexus Announces Two Key Executive Appointments March 15, 2017